Neurontin Class Action To Include Generics Buyers

Law360, New York (March 24, 2008, 12:00 AM EDT) -- A Philadelphia judge has ruled that Pfizer Inc. can be held liable for off-label marketing of generic versions of its blockbuster epilepsy drug Neurontin, allowing a class action including people who bought both brand-name and generic Neurontin to go forward.

On March 14, Judge Mark Bernstein of the Philadelphia County Court of Common Pleas denied a motion by Pfizer for partial summary judgment that a class action against it could not include patients who were prescribed gabapentin, the generic version of Neurontin. Judge Bernstein cited several...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.